Remepy
Remepy enables pharma companies to launch software-drug combinations. Remepy apps are tailored to specific clinical indications and drug mechanisms of action, increasing the drug’s efficacy. Engagement with Remepy apps activates brain mechanisms with a downstream impact on the immune system and direct improvement of synaptic connectivity and neuroplasticity.
www.remepy.com
The Founders
Stats
2022
Founded
2022
Partnered
Pre-Seed
First-Check
In The News
1.5.2024
Remepy raises $10 million Seed round to bring first hybrid drug to market
Remepy raises $10 million Seed round to bring first hybrid drug to market
The Israeli startup’s new hybrid drugs combine traditional drugs with its “digital molecules.” Digital molecules are therapeutic interventions that trigger physiological effects through the brain
Read More
14.2.2024
Naftali Bennett and Michal Tsur unite at Remepy: Former PM joins Board
This is the third high-tech board Bennett has joined since he left politics, previously joining AI cyber company Lasoo and quantum computing startup Quantum Source. Tsur and Bennett founded Cyota in 1999 together with Ben Enosh and Lior Golan and sold it to RSA Security in 2005 for $145 million.
Read More
1.5.2024
Remepy raises $10 million Seed round to bring first hybrid drug to market
Remepy raises $10 million Seed round to bring first hybrid drug to market
The Israeli startup’s new hybrid drugs combine traditional drugs with its “digital molecules.” Digital molecules are therapeutic interventions that trigger physiological effects through the brain
Read More
14.2.2024
Naftali Bennett and Michal Tsur unite at Remepy: Former PM joins Board
This is the third high-tech board Bennett has joined since he left politics, previously joining AI cyber company Lasoo and quantum computing startup Quantum Source. Tsur and Bennett founded Cyota in 1999 together with Ben Enosh and Lior Golan and sold it to RSA Security in 2005 for $145 million.
Read More